

FOOD AND DRUG ADMINISTRATION

Center for Drug Evaluation and Research

Oncologic Drugs Advisory Committee

AGENDA

March 31, 2009

8:30 a.m.	Call to Order Introduction of Committee	Chair, ODAC
	Conflict of Interest Statement	Nicole Vesely, Pharm.D. Designated Federal Official, ODAC

The committee will discuss supplemental biologic license application (sBLA) 125085/169, trade name Avastin (bevacizumab), Genentech, Incorporated, proposed indication, as a single agent, for the treatment of previously treated glioblastoma multiforme.

8:45 a.m. **FDA Presentation**

9:30 a.m. **Sponsor Presentation**

Genentech Inc.

10:15 a.m. *Break*

10:30 a.m. **FDA Presentation**

11:15 a.m. Questions to the Presenters

12:00 p.m. *Lunch*

1:00 p.m. Open Public Hearing

2:00 p.m. Questions to the ODAC and ODAC Discussion

3:00 p.m. *Break*

3:15 p.m. Questions to the ODAC and ODAC Discussion

4:30 p.m. Adjourn